ArticlePloS one2026
Myc and Skp2 overexpression promotes p27 ubiquitination and degradation in Ewing Sarcoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEwing sarcoma remains partially uncontrollable even after treatment with chemotherapy, surgery, and radiation therapy due to its high malignancy. To explore genes that drive Ewing sarcoma cell proliferation, we conducted a comprehensive analysis of mRNA expression. Based on cDNA array results, we identified consistently elevated expression of Myc and S-phase kinase-associated protein 2 (Skp2) across all five Ewing sarcoma cell lines examined.
methodsThe functional roles of Myc and Skp2 were assessed by siRNA-mediated knockdown and overexpression assays, followed by cell proliferation, cell cycle, and protein expression analyses. Ubiquitination of p27 and activation of the CCNE/CDK2 complex were evaluated by immunoprecipitation and western blotting. Finally, the in vivo relevance of Myc and Skp2 knockdown was validated using a xenograft mouse model.
resultsKnockdown (KD) using siRNAs specific for Myc and Skp2 resulted in reduced cell growth and an increased proportion of cells in the G0/G1 phase, indicating G1 arrest. In KD cells, we observed decreased CDK2 activity, increased p27 expression, and reduced expression of cyclin E (CCNE). The increased activity of the CCNE/CDK2 complex led to enhanced phosphorylation of p27 at Thr187, accelerating p27 degradation via Skp2-mediated ubiquitination. Concurrently, the CCNE/CDK2 complex promoted phosphorylation of Rb at Ser807/808, which is involved in E2F1 activation.
conclusionThis mechanism was identified through a comprehensive expression analysis aimed at uncovering the drivers of cell cycle acceleration in Ewing sarcoma. The findings offer new insights into therapeutic strategies for this malignancy, which has seen little progress in treatment over several decades. This discovery holds the potential to transform the current landscape, as no effective molecularly targeted therapies have yet been developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.